New RSV vaccine given during pregnancy protects newborns from disease, says Pfizer

A new respiratory syncytial virus (RSV) the vaccine protected newborns against severe cases of the disease in the critical months immediately after birth, drugmaker Pfizer announced (opens in a new tab) Tuesday (November 1). The single-dose vaccine was given to pregnant women during their second or third trimester, which triggered the production of protective antibodies which then crossed the placenta.

The company monitored the infants in the trial for six months after birth and found that during this time the vaccine was 69.4% effective in preventing severe cases of RSV that would require medical attention. However, firing efficiency was higher – about 81.8% – during the first three months of life.

Leave a Reply

Your email address will not be published. Required fields are marked *